Výsledky vyhledávání - "Poornima Shubhakar"

Data from Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

Autor: John Sarantopoulos, Min Zhu, Poornima Shubhakar, Marilyn Mulay, Monica M. Mita, Alain C. Mita, Shaunita A. Michael, Ian McCaffery, Devalingam Mahalingam, Jill Gilbert, Hongjie Deng, Yuying C. Hwang, Emily Chan, Gregory Friberg, Igor Puzanov, Lee S. Rosen

Purpose: This phase 1b dose-escalation study assessed safety, tolerability, and pharmacokinetics of ganitumab, a fully human monoclonal antibody against the insulin-like growth factor 1 (IGF1) receptor, combined with targeted agents or cytotoxic chem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92cc2ea087be5d33c3d1a12bd359087
https://doi.org/10.1158/1078-0432.c.6522288

Zobrazit plný text záznamu

Supplementary Tables 1 - 2 from Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

PDF file, 93KB, Supplemental Table 1. Study Drug Administration; Supplemental Table 2. Summary of Somatic Mutation Status and Tumor PTEN Expression Versus Best Result Change in Tumor Dimensions.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0feadbbe9882411297f5db732aac559d
https://doi.org/10.1158/1078-0432.22451769.v1

Zobrazit plný text záznamu

Supplementary Methods from Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

PDF file, 86KB.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b66812a2608d5ef0cb24c2fe4e8f400
https://doi.org/10.1158/1078-0432.22451772

Zobrazit plný text záznamu

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors

Autor: Shaunita A. Michael, Marilyn Mulay, Hongjie Deng, Jill Gilbert, John Sarantopoulos, Devalingam Mahalingam, Igor Puzanov, Ian McCaffery, Alain C. Mita, Min Zhu, Yuying C. Hwang, Lee S. Rosen, Gregory Friberg, Emily Chan, Monica M. Mita, Poornima Shubhakar

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 18(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ffe06966164666034f5754fd6e9515b
https://pubmed.ncbi.nlm.nih.gov/22510349

Zobrazit plný text záznamu

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

Autor: Min Zhu, Peter Rosen, Poornima Shubhakar, Hongjie Deng, Kelly S. Oliner, Christopher Sweeney, Darrin M. Beaupre, Abraham Anderson, Dorothy J. Park, Ian M. Leitch, Lorrin K. Yee

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 16(9)

Purpose: This phase Ib study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AMG 102, a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in combination with bevacizumab or m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8cf6b03fbffa986f7c686ad92c01d7b
https://pubmed.ncbi.nlm.nih.gov/20406832

Zobrazit plný text záznamu

First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors

Autor: Poornima Shubhakar, David S. Hong, Isaac Caudillo, A. Craig Lockhart, Siqing Fu, Yuying C. Hwang, Robert D. Loberg, Stephen J. Zoog, Hongjie Deng, Benny Amore, Peter Rosen, Peter D. Lee, Rabia Khan, Filip Janku, Razelle Kurzrock, Darrin M. Beaupre

Publikováno v: Journal of Clinical Oncology. 31:41-41

41 Background: AMG 208 is a small molecule MET inhibitor that suppresses proliferation and induces apoptosis in human tumor xenografts. This first-in-human study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 208. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76c2a59689f0167f9bf8805d1182a617
https://doi.org/10.1200/jco.2013.31.6_suppl.41

Zobrazit plný text záznamu

First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors

Autor: Gregory Friberg, Claire F. Verschraegen, Julie E. Bauman, Mark Stroh, Nilofer S. Azad, Michael A. Carducci, Rui Tang, Poornima Shubhakar, Channing J. Paller, Montaser Shaheen

Publikováno v: Journal of Clinical Oncology. 30:3009-3009

3009 Background: Aurora kinases A, B, and, C play essential roles in regulating cell division. Overexpression of aurora A and B in human tumors is associated with high proliferation rates and poor prognosis. AMG 900 is an investigational, orally admi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d4505eb5b53aa7544fc9e7b05cf2e47
https://doi.org/10.1200/jco.2012.30.15_suppl.3009

Zobrazit plný text záznamu

AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors

Autor: Lorrin K. Yee, Christopher Sweeney, P. J. Rosen, D. J. Park, C. Scripture, E. Rasmussen, Darrin M. Beaupre, Ian M. Leitch, J. Lu, Poornima Shubhakar

Publikováno v: Journal of Clinical Oncology. 26:3570-3570

3570 Background: AMG 102 is a novel, fully human monoclonal antibody that selectively targets hepatocyte growth factor/scatter factor (HGF/SF), the only ligand for the c-Met receptor, potentially i...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0313ac6cc68d48fbb2f20d041e238f8
https://doi.org/10.1200/jco.2008.26.15_suppl.3570

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání